Treatment-resistant depression: therapeutic trends, challenges, and future directions.
TLDR
Treatment-resistant depression continues to challenge mental health care providers, and further relevant research involving newer drugs is warranted to improve the quality of life of patients with the disorder.Abstract:
Background Patients with major depression respond to antidepressant treatment, but 10%-30% of them do not improve or show a partial response coupled with functional impairment, poor quality of life, suicide ideation and attempts, self-injurious behavior, and a high relapse rate. The aim of this paper is to review the therapeutic options for treating resistant major depressive disorder, as well as evaluating further therapeutic options. Methods In addition to Google Scholar and Quertle searches, a PubMed search using key words was conducted, and relevant articles published in English peer-reviewed journals (1990-2011) were retrieved. Only those papers that directly addressed treatment options for treatment-resistant depression were retained for extensive review. Results Treatment-resistant depression, a complex clinical problem caused by multiple risk factors, is targeted by integrated therapeutic strategies, which include optimization of medications, a combination of antidepressants, switching of antidepressants, and augmentation with non-antidepressants, psychosocial and cultural therapies, and somatic therapies including electroconvulsive therapy, repetitive transcranial magnetic stimulation, magnetic seizure therapy, deep brain stimulation, transcranial direct current stimulation, and vagus nerve stimulation. As a corollary, more than a third of patients with treatment-resistant depression tend to achieve remission and the rest continue to suffer from residual symptoms. The latter group of patients needs further study to identify the most effective therapeutic modalities. Newer biomarker-based antidepressants and other drugs, together with non-drug strategies, are on the horizon to address further the multiple complex issues of treatment-resistant depression. Conclusion Treatment-resistant depression continues to challenge mental health care providers, and further relevant research involving newer drugs is warranted to improve the quality of life of patients with the disorder.read more
Citations
More filters
Journal ArticleDOI
Dendritic Structural Plasticity and Neuropsychiatric Disease
TL;DR: The importance of recent genetic findings on the different mechanisms of structural plasticity are discussed and it is proposed that these converge on shared pathways that can be targeted with novel therapeutics.
Journal ArticleDOI
Treatment-resistant depression and peripheral C-reactive protein.
Samuel R. Chamberlain,Jonathan Cavanagh,Peter de Boer,Valeria Mondelli,Declan Jones,Wayne C. Drevets,Philip J. Cowen,Neil A. Harrison,Linda Pointon,Carmine M. Pariante,Edward T. Bullmore +10 more
TL;DR: It is suggested that patients with MDD stratified for proinflammatory biomarkers, like CRP, have a distinctive clinical profile that might be responsive to second-line treatment with anti-inflammatory drugs.
Journal ArticleDOI
Neural basis of major depressive disorder: Beyond monoamine hypothesis.
TL;DR: In this paper, two hypotheses have been proposed to explain the volume of the hippocampus: (i) neuroplasticity hypothesis; and (ii) neurogenesis hypothesis, which can explain the latency of response to antidepressants.
Journal ArticleDOI
Differential effects of psychotropic drugs on microbiome composition and gastrointestinal function.
Sofia Cussotto,Conall R. Strain,Conall R. Strain,Fiona Fouhy,Fiona Fouhy,Ronan Strain,Ronan Strain,Veronica L. Peterson,Gerard Clarke,Catherine Stanton,Catherine Stanton,Timothy G. Dinan,John F. Cryan +12 more
TL;DR: Data show that psychotropic medications differentially influence the composition of gut microbiota in vivo and that fluoxetine and escitalopram have specific antimicrobial activity in vitro, suggesting that the two factors are not causally linked.
Journal ArticleDOI
Adult Neurogenesis and Psychiatric Disorders
TL;DR: The evidence suggesting that adult hippocampal neurogenesis plays a role in emotional regulation and forms of learning and memory that include temporal and spatial memory encoding and context discrimination and that its dysregulation is associated with psychiatric disorders, such as affective disorders, schizophrenia, and drug addiction is reviewed.
References
More filters
Journal ArticleDOI
The serotonin syndrome.
TL;DR: The serotonin syndrome is a toxic condition requiring heightened clinical awareness for prevention, recognition, and prompt treatment, and further work is needed to establish the diagnostic criteria, incidence, and predisposing factors.
Journal ArticleDOI
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
TL;DR: There is growing evidence that the glutamatergic system is central to the neurobiology and treatment of mood disorders and exciting new prospects for the development of improved therapeutics for these devastating disorders are discussed.
Journal Article
The definition and meaning of treatment-resistant depression.
TL;DR: The Antidepressant Treatment History Form is presented as one method to formalize the evaluation of treatment adequacy and treatment resistance.
Journal ArticleDOI
Definition and epidemiology of treatment-resistant depression
TL;DR: Treatment-resistant depression patients can be defined as those who fail to respond to standard doses (i.e., significantly superior to placebo in double-blind studies) of antidepressants administered continuously for at least 6 weeks.
Journal Article
When at first you don't succeed: sequential strategies for antidepressant nonresponders.
Michael E. Thase,A.J. Rush +1 more
TL;DR: In this paper, alternate antidepressant strategies are reviewed within the context of a five-stage strategy, ranging from lesser to greater degrees of treatment resistance.